5 Minutes
It sounds almost unreal: a man in Norway may have been freed from HIV after receiving stem cells from his own brother. Not as an experimental shortcut, not as a targeted HIV therapy, but during treatment for a dangerous blood cancer that left doctors with few options and little room for error.
The patient, now known as the Oslo patient, was living with HIV after being diagnosed in 2006. Years later, in 2018, he was also diagnosed with myelodysplastic syndrome, a serious bone marrow disorder that disrupts the body’s ability to produce healthy blood cells. He responded to treatment at first, but the cancer came back two years later. At that point, doctors moved toward a stem cell transplant, a high-risk procedure generally reserved for patients with life-threatening blood diseases.
What happened next placed this case among the rarest in modern HIV research. The patient’s brother was already considered a suitable bone marrow match, which in itself is never guaranteed. Then came the surprise: testing showed the brother also carried a rare genetic mutation known as CCR5-delta 32. That detail changed everything.
For years, scientists have understood that HIV commonly enters immune cells by latching onto a receptor called CCR5. People who inherit two copies of the CCR5-delta 32 mutation are naturally resistant to the most common strains of HIV-1 because that receptor is altered in a way the virus struggles to use. It is an extremely unusual genetic trait, found in only a small fraction of the population.
In cases like this, a stem cell transplant does more than treat cancer. It can effectively rebuild the patient’s immune system using donor cells. If those donor cells carry the CCR5-delta 32 mutation, the new immune system may become far less vulnerable to HIV. That is the scientific hope. In the Oslo patient’s case, it appears to have become reality.
The transplant was not easy. The patient experienced complications, as many people do after such an aggressive procedure. But his body ultimately began producing new blood cells derived from the donated stem cells. Two years after the transplant, doctors made the careful decision to stop his antiretroviral therapy. That is the moment when any hidden HIV would usually be expected to rebound. It did not.
Now, four years after the transplant and two years after stopping HIV medication, repeated follow-up tests still show no detectable virus. His doctors say that, for all practical purposes, he appears to be cured. In the world of HIV medicine, where treatment can suppress the virus for decades but rarely erase it, those words carry enormous weight.
This is not the first time a stem cell transplant has led to long-term HIV remission or cure, but it is the first reported case involving a family donor. That detail makes the story even more striking. Siblings have only a limited chance of being a compatible bone marrow match, and the odds become even slimmer when a rare mutation like CCR5-delta 32 enters the equation. As one of the patient’s doctors told AFP, the man described it as winning the lottery twice.
That said, no one in the field is presenting this as a practical cure for the millions of people living with HIV worldwide. Stem cell transplantation is dangerous, expensive, and medically intense. It can be fatal. It is not a treatment doctors would ever recommend solely to eliminate HIV, especially when modern antiretroviral drugs already allow most patients to live long, healthy lives with the virus under control.
Still, rare cases like this matter far beyond the patient himself. They offer scientists a real-world blueprint for what an HIV cure might require: removing the cells the virus depends on, replacing them with resistant ones, and preventing the infection from finding a way back. Every successful case adds another piece to that puzzle.
The report, published in Nature Medicine, gives researchers fresh evidence that the CCR5 pathway remains one of the most important targets in the global search for an HIV cure. And while this kind of medical ending is too risky to become routine, it pushes the science one step closer to something once thought impossible.
For now, the Oslo patient stands as a reminder that in medicine, breakthroughs do not always arrive with fanfare. Sometimes they begin in a hospital room, with a family donor, a rare mutation, and a second chance nobody saw coming.
Source: gizmodo
Leave a Comment